The candidiasis market is growing steadily due to the high prevalence of the infection, the increasing awareness among people, and the availability of effective treatment options. The market is expected to grow further in the coming years due to the rising demand for antifungal drugs and the development of new treatment options. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the largest share of the market in 2020, and it is expected to maintain its dominance during the forecast period.
North America dominates the Candidiasis Market, accounting for the majority of the market share. The dominance of North America can be attributed to the increasing incidence of candidiasis, the presence of key market players, and favorable government initiatives. For instance, in June 2020, the FDA approved SCYNEXIS, Inc.'s ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC). The drug is the first and only oral antifungal approved for the treatment of VVC in over 20 years. Europe is the second-largest market for candidiasis, with the presence of key market players and increasing government initiatives driving the market growth. For instance, in October 2020, the European Medicines Agency (EMA) granted orphan drug designation to Amplyx Pharmaceuticals' APX001 for the treatment of candidiasis.
Read more @ https://influentialblogging.blogspot.com/2023/04/the-rising-prevalence-of-candidiasis_14.html
